# PPARG

Source: https://onco.cc/targets/pparg/  
OnCo record `pparg` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PPARG (Peroxisome proliferator-activated receptor gamma) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Thyroid cancer and Endometrial cancer.

## Summary

Ligand-activated transcription factor that forms obligate heterodimers with the retinoic acid receptor and acts as a key regulator of biological processes, such as adipocyte differentiation, lipid metabolism, glucose homeostasis and beta-oxidation of fatty acids. Activated by lipid ligands: binds peroxisome proliferators, such as hypolipidemic drugs, and fatty acids, such as prostaglandin J2 metabolites. Ligand-binding results in a conformational change in the receptor, promoting dissociation of repressors and recruitment of coactivators, and subsequent activation of target gene expression.

Open Targets scores its association with cancer at 0.79 (direct and indirect evidence; datatypes genetic literature 0.30, clinical 0.58, affected pathway 0.25, literature 1.00, genetic association 0.50, somatic mutation 0.93, animal model 0.38).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: peroxisome proliferator activated receptor gamma; Peroxisome proliferator-activated receptor gamma; PPARG1; PPARG2; NR1C3; PPARgamma
- Tags: cancer-genes-wave
- Symbol: PPARG
- Class: transcription
- Biology: Ligand-activated transcription factor that forms obligate heterodimers with the retinoic acid receptor and acts as a key regulator of biological processes, such as adipocyte differentiation, lipid metabolism, glucose homeostasis and beta-oxidation of fatty acids. Activated by lipid ligands: binds peroxisome proliferators, such as hypolipidemic drugs, and fatty acids, such as prostaglandin J2 metabolites. Ligand-binding results in a conformational change in the receptor, promoting dissociation of repressors and recruitment of coactivators, and subsequent activation of target gene expression. Specifically binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated pro-inflammatory responses. Plays a role in the regulation of cardiovascular circadian rhythms by regulating the transcription of BMAL1 in the blood vessels. Location: Nucleus; Cytoplasm (UniProt). Locus 3p25.2 (HGNC).
- Where found: Colorectal cancer: Open Targets association 0.59 with colorectal cancer (MONDO_0005575); Thyroid cancer: Open Targets association 0.56 with thyroid cancer (MONDO_0002108); Endometrial cancer: Open Targets association 0.54 with endometrial cancer (MONDO_0011962)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.58. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:9236: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9236
- UniProt P37231: https://www.uniprot.org/uniprotkb/P37231/entry
- NCBI Gene 5468: https://www.ncbi.nlm.nih.gov/gene/5468
- Ensembl ENSG00000132170: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000132170

## Connected records

- collections: [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Thyroid cancer](https://onco.cc/cancers/thyroid/)

---
JSON: https://onco.cc/api/v1/entities/pparg.json